Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...

Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...

latrobe.edu.au Aims (1) To investigate whether a daily acute:chronic workload ratio informs injury risk in Australian football players; (2) to identify which combination of workload variable, acute ...

So the arrival of a relatively safe and effective non-opioid drug to treat acute pain without the risk of addiction is a huge ...

Other symptoms of bronchitis include chest pain, breathlessness, a sore throat, a runny nose, and a high temperature, ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

pain, instability, and osteoarthritis. There is currently no consensus on treatment of acute or chronic UCL injuries. Our primary purpose was to compare nonoperative treatment with surgical repair ...

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that the first subject has been enrolled and ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.